Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults
Status:
Terminated
Trial end date:
2017-05-25
Target enrollment:
Participant gender:
Summary
This is a phase II study designed to investigate the combination of bortezomib with the
mitoxantrone reinduction regimen used in the ALL R3 trial. The study will enroll patients
with high risk ALL relapse including early bone marrow relapse and second or greater relapse
of any kind. Patients with relapsed LL will also be eligible. Bone marrow evaluation will be
performed after blood counts recover to assess the rate of CR (<5% bone marrow blasts) and
MRD status in children following this regimen. Further treatment with or without HSCT will be
at the discretion of the primary physician.